<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405743</url>
  </required_header>
  <id_info>
    <org_study_id>CP4055-106</org_study_id>
    <nct_id>NCT00405743</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies</brief_title>
  <official_title>A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clavis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clavis Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with refractory or relapsed hematologic malignancies will receive CP-4055
      intravenously(IV) on Day 1-5 every three weeks until complete response or disease
      worsening/progressing
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre clinical study conducted in the USA and in Europe. It is an open label,
      dose escalation study designed to characterize the safety, tolerability, pharmacokinetics
      (PK), and efficacy of CP-4055 as a single agent when administered as a 2 hours intravenous
      (IV) or a continuous IV (CIV) infusion administered daily for 5 days in a 21-day cycle,
      either alone or with idarubicin IV, in patients with refractory/relapsed hematologic
      malignancies who have either failed potentially curative therapy or are considered unsuitable
      for standard therapy.

      In a second phase of the study the efficacy of single agent CP-4055 in patients with AML may
      be assessed.

      It is intended that patients receive a minimum of two cycles of therapy in the absence of
      unacceptable toxicity or significant disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Determine the MTD and PK properties of CP-4055 single agent.</measure>
    <time_frame>Q4 2007</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Determine the efficacy of CP-4055 single agent in AML</measure>
    <time_frame>Q4 2007</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Evaluate the safety profile of CP-4055 single agent.</measure>
    <time_frame>Q4 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the MTD and PK of CP-4055 in combination with idarubicin.</measure>
    <time_frame>Q2 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Extended evaluation of the safety profile of CP-4055 single agent in AML</measure>
    <time_frame>Q2 2008</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Hematologic Malignancies</condition>
  <condition>AML</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CP4055, 2 and 4 hour IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CP-4055, Continuous IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-4055</intervention_name>
    <description>CP-4055 Continuous IV infusion</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-4055</intervention_name>
    <description>CP4055 2 and 4 hour IV infusion</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ARM A and B: Phase I CP-4055 single agent 1. Patients must have relapsed/refractory
        leukemias for which no standard therapies are anticipated to result in a durable response
        or have failed potentially curative therapy, or have refused or are considered unsuitable
        for standard therapy

        ARM C: CP-4055 in combination with idarubicin

          1. Patients with relapsed/refractory AML for which no standard therapies are anticipated
             to result in a durable response or who have failed potentially curative therapy, or
             who refuse or are considered unsuitable for standard therapy

             ARM A, B, C: CP-4055 as single agent and/or in combination with idarubicin

          2. Patients must be 18 years of age or older

          3. Patients must have ECOG performance status (PS) of 0 - 2. See Appendix 3

          4. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically
             sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to
             beginning treatment on this study. Nursing patients are excluded.

             Male and female patients must use acceptable contraceptive methods for the duration of
             time on study, and males also for 3 months after the last CP-4055 dose

          5. Patients must be capable of understanding and complying with parameters as outlined in
             the protocol, and able and willing to sign a written informed consent form

          6. In the absence of rapidly progressing disease, the interval from prior treatment to
             time of study drug administration should be at least 2 weeks for cytotoxic agents, or
             at least 5 half-lives for noncytotoxic agents.

          7. Patients must have the following clinical laboratory values:

               -  Serum creatinine less or equal to 1.5 x the institutional upper limit of normal
                  (ULN)

               -  Total bilirubin less or equal to 1.5 x the ULN unless considered due to Gilbert's
                  syndrome

               -  Alanine aminotransferase (ALT) (SGPT), or aspartate aminotransferase (AST) (SGOT)
                  less or equal to 2.5 x the ULN unless considered due to organ leukemic
                  involvement

        Phase II

        1. Patients with a confirmed diagnosis of AML who have received cytotoxic chemotherapy

        2 - 7. Identical to inclusion criteria nos. 2 - 7 for phase I

        Exclusion Criteria:

        Phase I AND II

          1. A history of allergic reactions or sensitivity attributed to compounds of similar
             chemical or biologic composition to CP-4055, i.e., ara-C and/or egg

          2. Known positive status for human immunodeficiency virus (HIV) or hepatitis B or C

          3. Pregnant and nursing patients are excluded

          4. Uncontrolled intercurrent illness

          5. Active heart disease

          6. Patients receiving any other standard or investigational cytotoxic treatment for their
             hematologic malignancy other than a maximum of 5 g of hydroxyurea to a maximum of 5
             days in cycle 1 of therapy

          7. Any medical condition which in the opinion of the investigator places the patient at
             an unacceptably high risk for toxicities

             Exclusion criteria no. 8 applies only in arm C:

          8. Patients with hypersensitivity to idarubicin or any other component of the product,
             and/or other anthracyclines or anthracenediones
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis J Giles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Drug Development (IDD), Cancer Therapy and Research Center, San Antonio, Texas, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mew York Medical College, Division of Oncology</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center (DUMC)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Drug Development (IDD), Cancer Therapy and Research Center, 7979 Wurzbach Rd.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Service, Hôpital Beaujon and Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <state>Paris</state>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire, CHU de Lyon, Service d'Hematologie Clinique</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire CHU de Toulouse, Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>40031-31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Benjamin Franklin Med.Clinic III</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine Klinikum der Johann Wolfgang Goethe-Universität Medizinische Klinik II</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westfälische Wilhelms-Universität Münster Medizinische Klinik und Polikinik Innere Medizin A</name>
      <address>
        <city>Münster</city>
        <zip>48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Medical Oncology L and A Serágnoli University of Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitá degli Studi di Roma Ematologia- Policlinico Tor Vergata</name>
      <address>
        <city>Rome</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Hematology, Ullevål University Hospital, University of Oslo</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2006</study_first_submitted>
  <study_first_submitted_qc>November 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2006</study_first_posted>
  <disposition_first_submitted>September 12, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>September 12, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 18, 2013</disposition_first_posted>
  <last_update_submitted>September 12, 2013</last_update_submitted>
  <last_update_submitted_qc>September 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CP-4055</keyword>
  <keyword>ELACYT™</keyword>
  <keyword>Cancer</keyword>
  <keyword>Refractory</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>AML</keyword>
  <keyword>AMM</keyword>
  <keyword>CLL</keyword>
  <keyword>CML</keyword>
  <keyword>CMML</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

